eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » GlaxoSmithKline - Comment

GlaxoSmithKline - Comment

Document ID: FDA-2010-N-0247-0004
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: September 03 2010, at 12:00 AM Eastern Daylight Time
Date Posted: September 16 2010, at 12:00 AM Eastern Standard Time
Comment Start Date: June 8 2010, at 12:00 AM Eastern Standard Time
Comment Due Date: September 7 2010, at 11:59 PM Eastern Standard Time
Tracking Number: 80b444ae
View Document:  View as format xml

View Comment

On behalf of GlaxoSmithKline, I am submitting this letter to provide comments on docket number FDA-2010-N-0247. GSK appreciates this opportunity to provide comments to FDA on this important and timely topic.

Attachments:

GlaxoSmithKline - Comment

Title:
GlaxoSmithKline - Comment

View Attachment: View as format pdf

Related Comments

    View All
Total: 16
Abbott Laboratories - Comment
Public Submission    Posted: 09/16/2010     ID: FDA-2010-N-0247-0003

Sep 07,2010 11:59 PM ET
GlaxoSmithKline - Comment
Public Submission    Posted: 09/16/2010     ID: FDA-2010-N-0247-0004

Sep 07,2010 11:59 PM ET
Pharmaceutical Research and Manufacturers of America (PhRMA) - Comment
Public Submission    Posted: 09/16/2010     ID: FDA-2010-N-0247-0005

Sep 07,2010 11:59 PM ET
Critical Path Institute - Comment
Public Submission    Posted: 09/16/2010     ID: FDA-2010-N-0247-0006

Sep 07,2010 11:59 PM ET
Gilead Sciences, Inc. - Comment
Public Submission    Posted: 09/16/2010     ID: FDA-2010-N-0247-0007

Sep 07,2010 11:59 PM ET